



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE

1st Edition

---

# CLSI EP47™

## Evaluation of Reagent Carryover Effects on Test Results

CLSI EP47 provides guidance for planning, performing, evaluating, and documenting reagent carryover experiments and guidance for ensuring that no significant reagent carryover occurs.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the *CLSI Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

## Evaluation of Reagent Carryover Effects on Test Results

Marvin Berman, PhD  
Norbert Gottschalk, PhD  
J. Rex Astles, PhD, FADLM  
Natalya Benina, PhD, MSc

Jesper V. Johansen, PhD, MS  
Marianne Le, MS  
Nils B. Person, PhD, FADLM  
Paul Wenz, MS

### Abstract

Clinical and Laboratory Standards Institute EP47—*Evaluation of Reagent Carryover Effects on Test Results* provides guidance for planning, performing, evaluating, and documenting reagent carryover experiments along with establishing that no significant reagent carryover occurs by a developer during the Establishment Stage of the Test Life Phases Model (see CLSI EP19<sup>1</sup>). End-user laboratories can use CLSI EP47 to investigate if suspect results are caused by reagent carryover. Assessment and mitigation of carryover risk is described.

CLSI EP47 is intended to promote uniformity in the evaluation of reagent carryover characteristics of medical laboratory measurement procedures across developers of *in vitro* diagnostic tests, regulatory organizations, and medical laboratories.

Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Reagent Carryover Effects on Test Results*. 1st ed. CLSI guideline EP47 (ISBN 978-1-68440-249-6 [Print]; ISBN 978-1-68440-250-2 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2024.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, and users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2024 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, or other product or material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

To read CLSI's full Copyright Policy, please visit our website at <https://clsi.org/terms-of-use/>.

## Suggested Citation

CLSI. *Evaluation of Reagent Carryover Effects on Test Results*. 1st ed. CLSI guideline EP47. Clinical and Laboratory Standards Institute; 2024.

CLSI EP47-Ed1

ISBN 978-1-558-2440-249-6 (Print)

ISBN 978-1-558-2440-250-2 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 44, Number 24

## Committee Membership

### Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>.

### Document Development Committee on Sample and Reagent Carryover

**Jesper V. Johansen, PhD, MS**  
**Chairholder**  
**Radiometer ApS**  
**Denmark**

Joshua Buse, PhD, DABCC  
 Roy Romanow Provincial Laboratory  
 Canada

Kara Mitchell, PhD  
 New York State Department of Health  
 USA

**Jeffrey E. Vaks, PhD**  
**Vice-Chairholder**  
**USA**

Michelle Renee Campbell, MS,  
 MLS(ASCP)<sup>CM</sup>, MB<sup>CM</sup>, SC<sup>CM</sup>  
 Mayo Clinic  
 USA

Marc J. Rump, MS, PhD, DABCC,  
 NRCC, DLM(ASCP), SC<sup>CM</sup>  
 Tennessee Department of Health  
 USA

**Johnathan Eric Stanford, D.HSc, MHA,**  
**MLS(ASCP)<sup>CM</sup>**  
**Secretary**  
**DHC Regional Medical Center**  
**USA**

Norbert Gottschalk, PhD  
 Roche Diagnostics  
 Germany

Nicole Tolan, PhD, DABCC  
 Brigham and Women's Hospital  
 USA

Anna Alfano, BS, MS  
 Siemens  
 USA

Adil Khan, MSc, PhD  
 Temple University Hospital  
 USA

Marvin Berman, PhD  
 Abbott  
 USA

Marina V. Kondratovich, PhD  
 FDA Center for Devices and  
 Radiological Health  
 USA

### Expert Panel on Evaluation Procedures

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>.

## Acknowledgment

---

CLSI, the Consensus Council, and the Document Development Committee on Sample and Reagent Carryover gratefully acknowledge the following volunteers for their important contributions to the development of CLSI EP47:

J. Rex Astles, PhD, FADLM  
Centers for Disease Control and  
Prevention  
USA

Marianne Le, MS  
Qufora A/S  
Denmark

Paul Wenz, MS  
Illumina, Inc.  
USA

Natalya Benina, PhD, MSc  
Fujirebio Diagnostics, Inc.  
USA

Kristen Meier, PhD  
Illumina, Inc.  
USA

Paula Ladwig, MS, MLS(ASCP)<sup>CM</sup>  
Mayo Clinic  
USA

Nils B. Person, PhD, FADLM  
USA


# Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	vii
<b>Chapter 1: Introduction .....</b>	<b>1</b>
1.1 Scope .....	1
1.2 Background .....	3
1.3 Assessing the Clinical Risk Associated With Carryover .....	3
1.4 Evaluation of Carryover Effects on the Results of Patients .....	4
1.5 Standard Precautions .....	4
1.6 Terminology .....	4
<b>Chapter 2: Path of Workflow .....</b>	<b>9</b>
<b>Chapter 3: Evaluation of Reagent Carryover .....</b>	<b>11</b>
3.1 General Considerations for the Measurement of Reagent Carryover .....	12
3.2 Risk Assessment .....	13
3.3 Evaluation of Reagent Carryover .....	16
3.4 Reagent Carryover Requirements .....	16
3.5 Recommendations for Stating Limitations .....	27
<b>Chapter 4: Conclusion .....</b>	<b>29</b>
<b>Chapter 5: Supplemental Information .....</b>	<b>31</b>
<b>References .....</b>	<b>32</b>
<b>Appendix A. Carryover Prevented by Design .....</b>	<b>33</b>
<b>Appendix B. Examples of a Risk Assessment .....</b>	<b>39</b>
<b>Appendix C. Example of Reagent Carryover Studies, Quantitative Measurement Procedures: Quantitative Assays .....</b>	<b>43</b>
<b>The Quality Management System Approach .....</b>	<b>50</b>

Currently in preview, click buy full version

## Foreword

Carryover is the unintended transfer of material from a patient sample or reagent into other samples, reagents, materials, or parts of the instrument system, potentially causing a carryover effect (ie, a quantifiable difference in a measurement result). CLSI EP47 focuses on carryover from a reagent into adjacent reagents, termed “reagent carryover.” Reagent carryover can potentially cause significant errors in reported results and, therefore, has the possibility of affecting medical decisions. Reagent carryover claims should be established as part of the Establishment Stage of a new test method (see Figure 1 and the detailed description of the Test Life Phases Model in CLSI EP19<sup>3</sup>).



Abbreviation: EP, evaluation protocols.

<sup>3</sup> The eight phases separate into the two stages, namely, Establishment Stage (blue), which is performed by a developer, and the Implementation Stage (purple), which is performed by the end-user laboratory.

**Figure 1. The Test Life Phases Model.**

CLSI EP47 recommends study designs and statistical methods for a developer to estimate a reagent carryover effect and to state the carryover performance, as appropriate. This guideline is also intended to assist developers to reduce carryover effects for commercial test methods. Worked examples are provided to illustrate study design considerations and data analysis.

**NOTE:** The content of CLSI EP47 is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### KEY WORDS

clinical effect

qualitative

quantitative

reagent carryover

study design

Currently in preview, click buy full version

# Chapter ①

## Introduction

# Evaluation of Reagent Carryover Effects on Test Results

## 1 Introduction

During the Establishment Stage of the Test Life Phases Model for a new test method, specifically the Feasibility and Design and Development phases, any unacceptable reagent carryover effect should be identified and mitigated. Developers should develop instrument systems and/or test methods (assays) with clinically insignificant or nondetectable carryover effects. Reagent carryover should be experimentally challenged during these two phases of the Test Life Phases Model to ensure any carryover effect is clinically insignificant. CLSI EP47 describes study designs for estimating the extent of reagent carryover. Before method development is concluded, a developer should experimentally determine that reagent carryover is within acceptable limits before finalizing the method. The study design could be used for evaluation or validation of reagent carryover. Reagent carryover is generally not verified by the end-user laboratory.

### 1.1 Scope

CLSI EP47 is for developers of instrument systems and medical laboratory test methods, both commercially manufactured as well as laboratory-developed tests (LDTs) to eliminate or mitigate reagent carryover. This guideline could also be used for the laboratory end user creating new LDTs, adding open-channel reagents not verified by the manufacturer, or investigating suspect results.

CLSI EP47 provides recommendations for:

- Risk assessment criteria to evaluate the potential for reagent carryover effects
- Statistically valid study designs for evaluation of reagent carryover effects
- Selection of sample(s) and/or reagent(s) combinations to include in reagent carryover studies
- Data analysis and interpretation
- Reporting and/or labeling format for a summary of the reagent carryover effect and performance claims

CLSI EP47 provides recommendations for the evaluation of reagent carryover from one reagent to another and is intended for quantitative test methods. Qualitative binary methods with an internal continual response and internal cutoff are covered by the recommendations in this guideline. However, CLSI EP47 does not cover semiquantitative test methods characterized as multilevel qualitative assays (eg, assays with an equivocal zone).

This guideline is not intended to provide detailed guidance for:

- The evaluation of sample carryover
- The combined effects of reagent carryover from several different reagents into a single reagent container
- Carryover between different test methods used to measure the same samples
- Carryover caused by sample interactions with reagents or cross-contamination from preexamination procedures
- Carryover within multianalyte assays and/or algorithmic test method

CLSI EP47 is not intended to be used for verification by the end-user laboratory but can be used to troubleshoot suspect results.